-
Fresenius Kabi to acquire Akorn for $4.3B
LAKE ZURICH, Ill. and LAKE FOREST, Ill. — Fresenius Kabi will acquire Akorn, manufacturer and marketer of prescription and over-the-counter pharmaceutical products, for approximately $4.3 billion, or $34 a share, plus the assumption of approximately $450 million of debt. The transaction is expected to close by early 2018 and to be accretive in 2018 to Fresenius Group net income and EPS, excluding integration costs.
-
BD to acquire Bard for $24B
FRANKLIN LAKES, N.J. and MURRAY HILL, N.J. — BD will acquire C. R. Bard, a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, for $317 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the boards of directors of both companies.